We are live on ! Find out more
PPCB icon

Propanc Biopharma
PPCB

4 hedge funds and large institutions have $69.5K invested in Propanc Biopharma in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more funds holding

Funds holding: 2 → 4 (+2)

0.12% more ownership

Funds ownership: 0.89% → 1.01% (+0.12%)

8% less capital inflows, than outflows

Capital inflows: $70.7K | Capital outflows: $77K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Securities
Two Sigma Securities
New York
+$28.2K
2
XTX Topco
XTX Topco
Cayman Islands
+$24.5K
3
Two Sigma Investments
Two Sigma Investments
New York
+$18K

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$71K
2
Marex Group
Marex Group
-$5.98K

PPCB Hedge Fund Activity: Q4 2025 in Review

4 of the 8,294 institutional investors tracked by Wall St. Rank reported a position in Propanc Biopharma (PPCB) for Q4 2025, worth a combined $69.5K — down 64% from $191K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PPCB positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $28.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $71K sold.

  • 4 institutional investors held Propanc Biopharma (PPCB) as of Q4 2025, up from 2 in Q3 2025.
  • Funds reported $69.5K of Propanc Biopharma stock for Q4 2025, down 64% quarter-over-quarter.
  • 3 funds opened new Propanc Biopharma positions in Q4 2025 and 1 closed out, a net change of +2 holders.
  • The largest Propanc Biopharma buyer in Q4 2025 was Two Sigma Securities, an estimated $28.2K added.
  • The largest Propanc Biopharma seller in Q4 2025 was Virtu Financial, an estimated $71K sold.

Based on aggregated 13F filings for Q4 2025.